Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
Angle (ANPCY) operates in the medical device and liquid biopsy diagnostics sector, where news coverage focuses on clinical research publications, regulatory milestones, and commercial partnerships. The company's Parsortix platform for circulating tumor cell analysis generates announcements related to scientific validation studies, pharmaceutical collaborations, and diagnostic assay development.
News coverage for this medical device manufacturer typically includes research publications demonstrating clinical applications of CTC analysis, announcements of commercial agreements with pharmaceutical companies for drug development programs, and updates on regulatory submissions. The company's focus on cancer diagnostics means news often highlights data from clinical studies evaluating the Parsortix system's performance across different cancer types and therapeutic monitoring applications.
Key news categories for Angle include clinical research findings published in peer-reviewed journals, FDA-related announcements regarding regulatory pathways for diagnostic products, commercial contract awards from pharmaceutical partners, and trading updates on business performance. The company's position in the emerging liquid biopsy field means developments in competitive technologies and regulatory frameworks for blood-based cancer testing also influence investor interest.
This news page provides comprehensive coverage of Angle's corporate announcements, research collaborations, and industry developments affecting the liquid biopsy diagnostics market. Bookmark this page to track regulatory progress, partnership announcements, and clinical validation milestones for this medical technology company.
ANGLE plc (OTCQX:ANPCY) announced it will present on the Investor Meet Company platform at 11:00 am (BST) on April 28, 2023. The session will feature insights from CEO Andrew Newland and CFO Ian Griffiths, focusing on the company's strategic activities. Investors have the opportunity to submit questions until April 26, 2023, that will be addressed during the presentation. ANGLE is known for its Parsortix system, the first FDA-cleared device for harvesting intact circulating tumor cells (CTCs) from blood, primarily for metastatic breast cancer. The technology shows promising clinical results in ongoing studies, demonstrating high accuracy in cancer detection and analysis. For details and registration, investors can visit the provided link.
ANGLE plc (OTCQX:ANPCY) reported significant milestones in its 2022 financial results, marking a breakthrough year with FDA clearance for the Parsortix PC1 Clinical System. This system allows for the harvesting of intact cancer cells from blood samples, a first in its class. The company achieved revenue of £1.0 million in 2022, consistent with 2021, while losses rose to £21.7 million due to planned investments. An encouraging performance in Q1 2023 reported strong year-on-year revenue growth. A major partnership with Solaris Health focuses on prostate cancer, and additional contracts with pharma clients highlight increasing demand for its services. ANGLE's healthy cash position stands at £31.9 million, complemented by ongoing R&D Tax Credits, setting a solid foundation for growth.
ANGLE plc has announced a development partnership with BioView Ltd. to create a circulating tumor cell (CTC) HER2 assay for breast cancer. This collaboration utilizes ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's microscopy technology. The first phase is projected to generate approximately £1.2 million in revenue. As breast cancer treatment evolves, there is a significant opportunity to develop a quantitative HER2 assay that can monitor patients' HER2 status over time. The HER2-low breast cancer segment, accounting for 55% of breast cancer cases, is gaining attention, especially with the introduction of targeted therapies like ENHERTU. Analysts anticipate a potential US$3 billion annual increase in sales value due to this market expansion.
FAQ
What is the current stock price of CELLBXHEALTH PLC (ANPCY)?
What is the market cap of CELLBXHEALTH PLC (ANPCY)?
